BRAF基因状态与西妥昔单抗联合化疗治疗晚期大肠癌疗效之间的关系

doi:10.3969/j.issn.1006-6233.2018.04.015

Abstract
Figure/Table
References
Related Citation (1)

Download: PDF (1626 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the relationship between BRAF gene status and efficacy of cetuximab combined with chemotherapy in the treatment of advanced colorectal cancer. Methods: 120 patients with advanced colorectal cancer were randomly divided into 2 groups. In group A, 61 cases of KRAS, NRAS, BRAF genes were wild type, using cetuximab combined with FOLFIRI (irinotecan, leucovorin, 5- fluorouracil) scheme; in group B, KRAS, NRAS genes were wild type in 59 cases, and BRAF gene was mutant, also using cetuximab combined with FOLFIRI scheme. The short-term efficacy, time to progression (TTP), overallsurvival (OS) and adverse reactions were compared between the two groups. Results: The objective response rate (ORR) and disease control rate (DCR) in group A and group B were 45.9%&42.4% and 83.6%&78.0%, respectively. TTP and OS in group A and group B were 10.5&9.1 months and 18.8&18.5 months, respectively. The results of A group were slightly better than those of group B, but there were no significant differences (P>0.05). The main adverse reactions of the two groups were acne like rash, digestive tract and hematological toxicity, mainly I-II degrees, but there were no statistical differences (P>0.05). Conclusion: Detection of BRAF gene status is helpful to further predict the value of cetuximab in advanced colorectal cancer, which may influence the treatment choice and prognosis of patients.

Key words： BRAF gene Cetuximab Advanced colorectal cancer

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2018.04.015 OR http://www.hbyxzzs.cn/EN/Y2018/V24/I4/583

[1] 曾进龙,王志超,张海良,等.FOLFIRI化疗方案及其与西妥昔单抗联用治疗晚期结肠癌分析[J].临床医学工程,2012,19(11):1929~1930.
[2] LI W,Qtu T,LING Y,et al.Molecular pathological epidemiologyof colorectal cancer in Chinese patients with KRAS and BRAFmutations[J].Oncotarget,2015,6(37):39607.
[3] Ciardiello F,Normanno N,Maiello E,et al.Clinical activity of FOLFIRI plus cetuximab according to extended genemutation status by next-generation sequencing:findings from the CAPRIGOIM trial [J].Ann Oncol,2014,25(9):1756~1761.
[4] Bokemeyer C,Van cutsem E,Rougier P,et al.Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer:pooled analysis of the CRYSTAL and OPUS randomised clinical trials [J].Eur Cancer,2012,48(10):1466~1475.
[5] Li Z,Liu XW,Chi ZC,et al.Detection of K-ras mutations in predicting efficacy of epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor in patients with metastatic colorectal cancer[J].PLoS One,2015,10(5):e0101019.
[6] 李艳艳,高静,杨蕊,等.结直肠癌Ras、BRAF和PIK3CA基因突变分析及与临床病理特征的关系[J].临床肿瘤学杂志,2016,21(1):27~33.
[7] Maughan TS,Adams RA,Smith CG,et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of therandomized phase 3 MRC COIN trial[J].Lancet,2011,377(9783):2103~2114.
[8] 刘影,郑细闰,朱亚珍,等.252例结直肠癌组织中KRAS、NRAS、BRAF、PIK3CA的基因突变分析[J].临床与实验病理学杂志,2016,32(8):851~855.
[9] 韦青,王晰程,沈琳.Braf突变晚期结直肠癌的治疗进展[J].临床肿瘤学杂志,2016,21(3):282~286.
[10] Kadowaki S,Kakuta M,Takahashi S,et al.Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer[J].World Gastroenterol,2015,21(4):1275~1283.
[11] Martinetti D,Costanzo R,Kadare S,et al.KRAS and BRAFmutational status in colon cancer from Albanianpatients[J].Diagn Pathol,2014,9:187.
[12] Yuan ZX,Wang XY,Qin QY,et al.The prognostic role of BRAF mutation in metastatic colorectal cancer receiving anti-EGFR monoclonal antibodies:a meta-analysis[J].PLOS One,2013,8(6):e65995.
[13] Ahn TS,Jeong D,Son MW,et al.The BRAF mutation is associated with the prognosis in colorectal cancer[J].Cancer Res Clin Oncol,2014,140(11):1863~1871.